Nektar Therapeutics Reports Positive 52-Week Phase 2b Results for Rezpegaldesleukin in Alopecia Areata, Advancing to Phase 3

summarizeSummary

Nektar Therapeutics announced positive 52-week Phase 2b results for rezpegaldesleukin in severe alopecia areata, showing deepening of responses and a favorable safety profile, paving the way for Phase 3 development.

check_boxKey Events

• Positive 52-Week Phase 2b Results

  The REZOLVE-AA study of rezpegaldesleukin in severe-to-very-severe alopecia areata demonstrated positive 52-week topline results, showing deepening of clinical responses with continued treatment.

• Statistically Significant Efficacy

  At week 52, 25.8% (low dose) and 27.6% (high dose) of patients achieved SALT Score ≤20 (80%+ hair coverage) versus 6.7% for placebo (p=0.049). Similarly, 30.2% (low dose) and 35.0% (high dose) achieved SALT Score ≤30 (70%+ hair coverage) versus 8.4% for placebo (p=0.023).

• Favorable Safety Profile Maintained

  A favorable safety and tolerability profile was observed over 52 weeks, consistent with prior studies. Nearly all treatment-emergent adverse events were mild-to-moderate, with 94% of patients completing the extension period and no discontinuations due to adverse events.

• Advancement to Phase 3 Development

  The positive results support the advancement of rezpegaldesleukin into late-stage development. The company plans an End of Phase 2 meeting with the FDA in Q2 2026 to align on the Phase 3 registrational strategy.

auto_awesomeAnalysis

Nektar Therapeutics has announced highly positive 52-week topline results from its REZOLVE-AA Phase 2b study for rezpegaldesleukin in severe-to-very-severe alopecia areata. The data demonstrates a deepening of clinical responses over time, with statistically significant improvements in hair regrowth (SALT scores) compared to placebo. Crucially, the drug maintained a favorable safety and tolerability profile throughout the 52-week treatment period, which is a key differentiator from existing treatments like JAK inhibitors. These robust results are critical as they support the advancement of rezpegaldesleukin into Phase 3 development, a major milestone that significantly de-risks the program and could transform the treatment landscape for alopecia areata. This positive news reinforces the company's pipeline strength and comes as the stock is trading near its 52-week high, suggesting strong investor confidence in its clinical programs.